Seeking Alpha EN

Fennec Pharmaceuticals GAAP EPS of -$0.17 misses by $0.21, revenue of $13.78M misses by $0.95M

Mar 24, 2026 &03292424202631; 11:29 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -72/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Fennec Pharmaceuticals missed both EPS (-$0.17 vs -$0.04 expected) and revenue ($13.78M vs $14.73M expected) in recent earnings. Fresh miss with market still digesting; biotech sector under pressure despite broad market strength.

AI CONFIDENCE

68% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

FENN

FENNStock

Expected to decline

Double miss on EPS and revenue; biotech earnings misses typically trigger 3-8% downside within 24h, especially for smaller-cap pharma with limited revenue base

⇅

S&P 500

^GSPCIndex

High volatility expected

Broad market up +1.15% but VIX elevated at 26.45; individual biotech misses unlikely to move large-cap index, but sector rotation risk exists

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

FENN likely to gap down at open or within 2h. Confidence 68 (not higher) due to small-cap liquidity and potential short squeeze. Skip if position size cannot absorb 5%+ slippage. Better risk/reward on sector shorts (biotech ETFs) if conviction is high. [MOVE:3.5%]

KEY SIGNALS

Fresh earnings miss (17 min old) — market reaction still unfoldingEPS miss of $0.21 is material (525% worse than expected)Revenue miss of $0.95M (~6.5% shortfall) suggests demand/execution issuesVIX elevated despite S&P strength — risk-off sentiment in small/mid-cap biotech

SECTORS INVOLVED

HealthcareBiotechnologyPharmaceuticals

Analysis generated on Mar 24, 2026 at 11:46 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Fennec Pharmaceuticals GAAP EPS of -$0.17 misses by $0.21, revenue of $13.78M misses by $0.95M

RELATED INTELLIGENCE